FDA Adverse Event Injury Summary report: N

REZUM

MDR report key: 24185655 · Received January 26, 2026

Report

Report Number
2124215-2026-04596
Event Type
Injury
Date Received
January 26, 2026
Date of Event
January 1, 2023
Report Date
February 23, 2026
Manufacturer
BOSTON SCIENTIFIC CORPORATION
Product Code
KNS
Adverse Event
Yes
Report Source
Manufacturer report
Reporter Location
FR
Reporter Occupation
PHYSICIAN
Health Professional
Yes

Narratives

Additional Manufacturer Narrative · 0

DETAILED PRODUCT INFORMATION WAS NOT PROVIDED TO BSC. WE COMPLETED A GOOD FAITH EFFORT TO OBTAIN THE INFORMATION. BECAUSE THE PRODUCT IS UNKNOWN AT THIS TIME, WE ARE UNABLE TO PROVIDE THE COMPLETE UDI AND OTHER PRODUCT SPECIFIC INFORMATION. IF ADDITIONAL DETAILS BECOME AVAILABLE, A SUPPLEMENTAL REPORT WILL BE SUBMITTED. KLEIN, C., ANRACT, J., PINAR, U., CHEVROT, A., DELLA NEGRA, E., FASSI-FEHRI, H., GAS, J., ROUSCOFF, Y., WILISCH, J., SARAZIN, C., DOIZI, S., & LEBDAI, S. (2025). SURGICAL AND INTERVENTIONAL MANAGEMENT OF BLADDER OUTLET OBSTRUCTION RELATED TO BENIGN PROSTATIC HYPERPLASIA: SYSTEMATIC REVIEW OF THE LITERATURE AND CLINICAL PRACTICE GUIDELINES FROM THE FRENCH MALE LUTS COMMITTEE (CTMH). THE FRENCH JOURNAL OF UROLOGY, 35(11), 102951. HTTPS://DOI.ORG/10.1016/J.FJUROL.2025.102951.

Additional Manufacturer Narrative · 0

THERE WAS NO DEVICE AVAILABLE FOR ANALYSIS; THEREFORE, NO PHYSICAL OR VISUAL ANALYSIS OF THE PRODUCT COULD BE PERFORMED. THE REPORTED PATIENT SYMPTOMS ARE A KNOWN RISK ASSOCIATED WITH THESE DEVICES AS INDICATED IN THE INSTRUCTIONS FOR USE. BASED ON THE INFORMATION AVAILABLE, A CONCLUSION CODE OF KNOWN INHERENT RISK OF DEVICE WAS ASSIGNED TO THIS INVESTIGATION. DETAILED PRODUCT INFORMATION WAS NOT PROVIDED TO BSC. WE COMPLETED A GOOD FAITH EFFORT TO OBTAIN THE INFORMATION. BECAUSE THE PRODUCT IS UNKNOWN AT THIS TIME, WE ARE UNABLE TO PROVIDE THE COMPLETE UDI AND OTHER PRODUCT SPECIFIC INFORMATION. IF ADDITIONAL DETAILS BECOME AVAILABLE, A SUPPLEMENTAL REPORT WILL BE SUBMITTED. KLEIN, C., ANRACT, J., PINAR, U., CHEVROT, A., DELLA NEGRA, E., FASSI-FEHRI, H., GAS, J., ROUSCOFF, Y., WILISCH, J., SARAZIN, C., DOIZI, S., & LEBDAI, S. (2025). SURGICAL AND INTERVENTIONAL MANAGEMENT OF BLADDER OUTLET OBSTRUCTION RELATED TO BENIGN PROSTATIC HYPERPLASIA: SYSTEMATIC REVIEW OF THE LITERATURE AND CLINICAL PRACTICE GUIDELINES FROM THE FRENCH MALE LUTS COMMITTEE (CTMH). THE FRENCH JOURNAL OF UROLOGY, 35(11), 102951. HTTPS://DOI.ORG/10.1016/J.FJUROL.2025.102951.

Description of Event or Problem · 0

IT WAS REPORTED TO BOSTON SCIENTIFIC VIA AN ARTICLE PUBLISHED IN THE FRENCH JOURNAL OF UROLOGY THAT A SYSTEMATIC REVIEW WAS CONDUCTED TO UPDATE THE FRENCH RECOMMENDATIONS PUBLISHED IN 2021, AS WELL AS THE 2024 EUROPEAN ASSOCIATION OF UROLOGY GUIDELINES, ON THE SURGICAL AND INTERVENTIONAL MANAGEMENT OF BLADDER OUTLET OBSTRUCTION RELATED TO BENIGN PROSTATIC HYPERPLASIA. THE REVIEW OF THE LITERATURE WAS PERFORMED THROUGH PUBMED FROM 2023-2025, COMPLEMENTING THE DATA ALREADY INCLUDED IN PREVIOUS GUIDELINES. THIS PROCESS WAS BASED ON A PREDEFINED BIBLIOGRAPHIC STRATEGY, FOLLOWED BY A CRITICAL ANALYZE OF THE PUBLICATIONS WITH ASSIGNMENT OF LEVELS OF EVIDENCE, FORMULATION OF CONCLUSIONS, AND DEVELOPMENT OF RECOMMENDATIONS ADDRESSING SPECIFIC CLINICAL QUESTIONS. FOR REZUM PROCEDURES, AN ADVERSE EVENT EXPERIENCED BY THE PATIENTS WAS ACUTE URINARY RETENTION, AND SURGICAL RETREATMENT AND MEDICATION RESTART WERE REQUIRED. REZUM MAY BE OFFERED AS A SURGICAL OPTION FOR MEN WITH MODERATE-TO-SEVERE LUTS, DESIRING EJACULATORY PRESERVATION, AND WITH PROSTATE VOLUMES OF 30-80 ML.

Description of Event or Problem · 0

IT WAS REPORTED TO BOSTON SCIENTIFIC VIA AN ARTICLE PUBLISHED IN THE FRENCH JOURNAL OF UROLOGY THAT A SYSTEMATIC REVIEW WAS CONDUCTED TO UPDATE THE FRENCH RECOMMENDATIONS PUBLISHED IN 2021, AS WELL AS THE 2024 EUROPEAN ASSOCIATION OF UROLOGY GUIDELINES, ON THE SURGICAL AND INTERVENTIONAL MANAGEMENT OF BLADDER OUTLET OBSTRUCTION RELATED TO BENIGN PROSTATIC HYPERPLASIA. THE REVIEW OF THE LITERATURE WAS PERFORMED THROUGH PUBMED FROM 2023-2025, COMPLEMENTING THE DATA ALREADY INCLUDED IN PREVIOUS GUIDELINES. THIS PROCESS WAS BASED ON A PREDEFINED BIBLIOGRAPHIC STRATEGY, FOLLOWED BY A CRITICAL ANALYZE OF THE PUBLICATIONS WITH ASSIGNMENT OF LEVELS OF EVIDENCE, FORMULATION OF CONCLUSIONS, AND DEVELOPMENT OF RECOMMENDATIONS ADDRESSING SPECIFIC CLINICAL QUESTIONS. FOR REZUM PROCEDURES, AN ADVERSE EVENT EXPERIENCED BY THE PATIENTS WAS ACUTE URINARY RETENTION, AND SURGICAL RETREATMENT AND MEDICATION RESTART WERE REQUIRED. REZUM MAY BE OFFERED AS A SURGICAL OPTION FOR MEN WITH MODERATE-TO-SEVERE LUTS, DESIRING EJACULATORY PRESERVATION, AND WITH PROSTATE VOLUMES OF 30-80 ML.

Devices

Seq Brand Generic Product Code Manufacturer Model Lot UDI-DI
246981 REZUM UNIT, ELECTROSURGICAL ENDOSCOPIC (WITH OR WITHOUT ACCESSORIES) KNS BOSTON SCIENTIFIC CORPORATION

Patients

Seq Age Sex Outcome Treatment
1 NA Unknown Required Intervention